Concepedia

Evaluation of the efficacy and safety of oral tiludronate in paget's disease of bone

Jean‐Yves Reginster, François Colson, G Morlock, Bernard Combe, D Ethgen, Piet Geusens

Arthritis & Rheumatism · 1992 · 52 citations · 23 references

DOI

Abstract

Because of its significantly better antiresorptive effects and greater analgesic properties (compared with lower dosages), combined with the excellent clinical and biochemical tolerance, the 800-mg daily dose of tiludronate appears to be optimal for the treatment of Paget's disease of bone.

References

23

Diphosphonates Inhibit Hydroxyapatite Dissolution in vitro and Bone Resorption in Tissue Culture and in vivo

H. Fleisch, R. Graham, R.G.G. Russell et al. · Science · 1969 · 758 citations

, , +13

Nuclear Inclusions in Paget's Disease of Bone

Barbara G. Mills, Frederick R. Singer · Science · 1976 · 274 citations

, , +9

TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)

W. B. Frijlink, OlavL.M. Bijvoet, J. te Velde et al. · The Lancet · 1979 · 258 citations

, , +4

The Influence of Two Diphosphonates on Calcium Metabolism in the Rat

Andreas Gasser, D.B. Morgan, H. Fleisch et al. · Clinical Science · 1972 · 202 citations

, , +17

Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

H.I.J. Harinck, Socrates E. Papapoulos, H J Blanksma et al. · BMJ · 1987 · 184 citations · Full text

, , +15